Sequencing Study from Roswell Park Highlights Previously Unknown Myeloma Resistance Mechanisms

— A group of researchers led by Maximillian Merz, MD, Assistant Professor of Oncology with the Myeloma team at Roswell Park Comprehensive Cancer Center, conducted the first prospective clinical trial investigating spatial heterogeneity in patients with either relapsed/refractory or newly diagnosed multiple myeloma. Findings from the study will be presented today at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held virtually.

Read more

Novel Therapy is Safe for Non-Hodgkin Lymphoma Patients, Roswell Park-Led Study Finds

Roswell Park Comprehensive Cancer Center’s Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Dr. Hernandez-Ilizaliturri will present the team’s findings today at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held virtually.

Read more

Circulating tumor DNA indicates increased risk of relapse after stem cell transplant in patients with diffuse large B-cell lymphoma

Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists suggests that patients whose blood or stem cell samples harbor tumor DNA are likely to relapse.

Read more

Combination of chemotherapy and blinatumomab improves survival for patients with B-cell acute lymphoblastic leukemia

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).

Read more

Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers

The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.

Read more

CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

Read more

Rutgers Cancer Institute of New Jersey to Present Expansive New Hematology Data at the 62nd ASH Annual Meeting and Exposition

The American Society of Hematology (ASH), is the world’s largest professional society with a focus on the causes and treatment of blood disorders. Experts from Rutgers Cancer Institute of New Jersey will be presenting a variety of key hematology data at the 62nd American Society of Hematology Annual Meeting. This includes 22 scheduled presentations, including 10 oral presentations examining several types of blood cancers including leukemia, lymphoma, and myeloma.

Read more